Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F-652 in COVID-19 Pneumonia
NCT05205668Phase 2Withdrawn
- Sponsor
- Evive Biotech
- Start
- Apr 2022
- Primary completion
- Apr 2022
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of eflepedocokin alfa in COVID-19 pneumonia, sponsored by Evive Biotech. Planned start Apr 2022; status: withdrawn.
02
Drugs
eflepedocokin alfa
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT05205668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05205668.